Welcome to our dedicated page for KATN news (Ticker: KATN), a resource for investors and traders seeking the latest updates and insights on KATN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KATN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KATN's position in the market.
TuHURA Biosciences (NASDAQ:HURA) reported its fiscal year 2024 results and corporate updates. The company plans to initiate enrollment in Phase 3 IFx-2.0 trial for advanced Merkel cell carcinoma in Q2 2025, conducted under Special Protocol Assessment Agreement with FDA. The trial will test IFx-2.0 as adjunctive therapy with Keytruda®.
Key financial highlights include R&D expenses of $13.3 million (up from $9.4 million in 2023) and G&A expenses of $4.3 million (slight increase from $4.1 million in 2023). The company raised $36 million in 2024 to fund operations through late Q4 2025.
Notable developments include:
- Planned acquisition of Kineta's Phase 2 ready VISTA inhibitor, expected to close in Q2 2025
- NASDAQ listing achievement via reverse merger
- Expansion of discovery team for immune modulating Antibody Drug/Peptide Conjugate Program
